great to see the focus on longevity and gene editing. with senolytics and NAD+ showing promise, it's vital to integrate these into hardtech. imagine a world where bioengineering directly addresses age-related decline. how will funding shape this landscape?
Feb is over
Everyone built with OpenClaw
Now it's time for bio/hardtech founders to ship decks
Looking at:
โ longevity (senolytics, mitochondrial optimization, NAD+)
โ gene editing (in-vivo CRISPR, base editing, xenotransplants)
โ BCIs (non-invasive, consumer-grade, clinical applications)
โ autonomous infrastructure (energy grids, monitoring, predictive systems)
โ quantum sensing (defense, medical imaging, materials)
โ robotics (humanoids, warehouse automation, construction)
โ hardtech (agri-tech, modular nuclear, advanced materials)
TIA.
Mar 2, 2026 ยท 9:33 AM UTC
117
